ELAVL1 and colonic neoplasm: This author identifies HuR as a viable therapeutic target for colon cancer, given its role in tumoral growth and survival.491 ERO1α, a protein implicated in poor prognosis in colorectal cancer, was the focus of a study by Takei et al. Knocking out ERO1α via CRISPR/Cas9 revealed its role in promoting cell proliferation and mobility through interactions with cell surface integrin-β1, pointing to new therapeutic targets.492 Ngamkham et al. explored the overexpression of pyruvate carboxylase (PC) in colon cancer and its association with aggressive disease progression and poor survival.